clinical trial · NCT01458405
Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration
Myocardial InfarctionCAP-1002 Allogeneic Cardiosphere-Derived CellsPlacebo
brief summary
The purpose of this study is to determine whether Allogeneic Cardiosphere-Derived Cells (CAP-1002) is safe and effective in decreasing infarct size in patients with a myocardial infarction.
started
Nov 13, 2012
primary completion
Jul 3, 2017
completion
Feb 28, 2019
last updated
Apr 9, 2024
official title
Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol